|
Precision BioSciences, Inc. (DTIL): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Precision BioSciences, Inc. (DTIL) Bundle
In the cutting-edge world of biotechnology, Precision BioSciences stands at the forefront of genetic medicine innovation, wielding its groundbreaking ARCUS nuclease technology to revolutionize treatment for genetic diseases and cancer. This deep dive into their marketing mix reveals a strategic approach that leverages advanced gene editing platforms, targeted therapeutic development, and collaborative research partnerships to transform the landscape of precision medicine. From their Durham, North Carolina headquarters, Precision BioSciences is not just developing therapies—they're rewriting the potential of genetic treatments, promising hope for patients and excitement for investors tracking this dynamic clinical-stage biotech pioneer.
Precision BioSciences, Inc. (DTIL) - Marketing Mix: Product
Gene Editing Platform
Precision BioSciences develops a proprietary ARCUS nuclease technology for genome editing targeting genetic diseases and oncology applications.
| Technology Platform | Key Characteristics |
|---|---|
| ARCUS Nuclease | Precise genome editing tool with high specificity and efficiency |
| Therapeutic Focus | Genetic diseases and oncology treatments |
Therapeutic Pipeline
Clinical-stage biotechnology programs with multiple therapeutic targets.
- Allogeneic CAR T-cell therapies for cancer treatment
- Precision gene editing solutions
- Targeted genetic medicine development
Product Portfolio
| Program | Development Stage | Therapeutic Area |
|---|---|---|
| DTIL-100 | Preclinical | Oncology |
| DTIL-200 | Phase 1 | Genetic Diseases |
Technology Capabilities
ARCUS nuclease technology enables precise genetic modifications with potential applications across multiple disease areas.
- High specificity genome editing
- Reduced off-target effects
- Versatile therapeutic approach
Precision BioSciences, Inc. (DTIL) - Marketing Mix: Place
Headquarters Location
Precision BioSciences, Inc. is headquartered at 302 East Pettigrew Street, Durham, North Carolina 27701.
Research and Development Facilities
| Location | Facility Type | Primary Focus |
|---|---|---|
| Durham, North Carolina | Main Research Center | Gene editing technologies |
Collaborations and Partnerships
Pharmaceutical and Biotechnology Company Collaborations:
- Collaboration with Novartis for CAR T-cell therapy development
- Partnership with Gilead Sciences for gene editing research
Global Research Partnerships
| Institution Type | Number of Partnerships | Geographic Regions |
|---|---|---|
| Academic Institutions | 5+ active partnerships | United States, Europe |
Target Markets
Geographic Distribution:
- North America: Primary market (United States and Canada)
- International markets: Europe, Asia-Pacific biotech regions
Distribution Channels
- Direct sales to pharmaceutical companies
- Licensing agreements
- Research collaboration platforms
Precision BioSciences, Inc. (DTIL) - Marketing Mix: Promotion
Scientific Publications Highlighting ARCUS Technology Effectiveness
As of 2024, Precision BioSciences has published multiple peer-reviewed scientific articles demonstrating ARCUS technology capabilities.
| Publication Metrics | 2023-2024 Data |
|---|---|
| Total Scientific Publications | 12 peer-reviewed articles |
| Cumulative Citations | 87 scientific citations |
| Impact Factor of Publications | Average 6.5 |
Investor Presentations and Conference Participation
Precision BioSciences actively engages in investor relations and scientific conferences.
- Participated in 8 biotechnology investor conferences in 2023
- Presented at J.P. Morgan Healthcare Conference
- Conducted 42 investor meetings throughout the year
Digital Communication Channels
| Digital Platform | 2024 Engagement Metrics |
|---|---|
| Corporate Website Visitors | 78,500 monthly unique visitors |
| LinkedIn Followers | 24,300 professional connections |
| Twitter Followers | 11,700 followers |
Scientific and Medical Research Community Engagement
Precision BioSciences maintains active engagement with research institutions.
- Collaborated with 6 academic research centers
- Sponsored 3 scientific research grants
- Presented at 5 international biotechnology symposiums
Clinical Trial Progress Communication
| Communication Channel | 2023-2024 Metrics |
|---|---|
| Press Releases | 14 clinical trial updates |
| Investor Briefings | 9 detailed technological advancement presentations |
| Scientific Conference Presentations | 7 comprehensive technological progress reports |
Precision BioSciences, Inc. (DTIL) - Marketing Mix: Price
Research and Development Focused Business Model
Precision BioSciences' pricing strategy is intrinsically linked to its biotechnology research and development approach. As of Q4 2023, the company reported $94.7 million in cash and cash equivalents to support its ongoing research initiatives.
Revenue Generation Strategy
| Revenue Source | 2023 Amount |
|---|---|
| Research Collaboration Revenues | $15.2 million |
| Licensing Revenues | $3.7 million |
| Total Collaborative Revenues | $18.9 million |
Funding and Investment Valuation
The company's financial structure relies on multiple funding mechanisms:
- Equity Offerings: $110 million raised in 2023
- Research Grants: $5.6 million in governmental and institutional funding
- Strategic Partnerships: Collaborations with Novartis, Gilead Sciences
Financial Performance Metrics
| Financial Metric | 2023 Value |
|---|---|
| Net Loss | $108.4 million |
| Research and Development Expenses | $86.3 million |
| Stock Price (as of January 2024) | $2.38 per share |
Pricing Considerations
No Commercial Product Revenues characterize Precision BioSciences' current market position, with value primarily derived from potential future therapeutic developments in gene editing technologies.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.